DSM Biologics (www.dsm.com) and Crucell (www.crucell.com) entered into a non-exclusive PER.C6® research licensing deal with Sartorius Biotech (www.sartorius.com). Sartorius will use the technology to evaluate mAbs produced using PER.C6 cells for calibrating and testing equipment products useful in the manufacture and/or purification of recombinant mAbs. Crucell and Sartorius further agreed to expand their PER.C6 collaboration by sharing technology and data on antibody production. Crucell’s and DSM’s PER.C6 technology platform has been developed for the large-scale manufacture of biopharmaceutical products, including vaccines.
